The Public Purview

Web Desk TPP

Experimental lung cancer drug gotistobart showed longer overall survival than docetaxel in a Phase 3 clinical trial.

Experimental Lung Cancer Drug Gotistobart

September 15, 2026

WASHINGTON: An experimental antibody drug called gotistobart has shown promising results in a clinical trial for patients with advanced squamous non-small cell lung cancer,…

Follow The Public Purview on WhatsApp